Up-regulation of long non-coding RNA SUMO1P3 is associated with poor prognosis in NSCLC patients

Recently, long noncoding RNAs (lncRNAs) have been shown to have crucial regulatory roles in human cancer biology and may be used for cancer diagnosis, prognosis, and potential therapeutic targets. LncRNA SUMO1P3 (Small ubiquitin-like modifier 1 pseudogene 3) is a newly identified lncRNA that was previously reported to be up-regulated in gastric cancer and bladder cancer, however, its role in non-small cell lung cancer (NSCLC) remains unclear. The aim of this study was to investigate the expression and clinical significance of lncRNA SUMO1P3 in NSCLC. Our results showed that SUMO1P3 was significantly up-regulated in NSCLC tissues compared with paired-adjacent nontumorous tissues (P< 0.01) and healthy tissues (P< 0.01). Its expression level was significantly correlated with TNM stage (X-2= 12.49, P= 0.0019< 0.001) and tumor size (X-2= 10.20, P= 0.0014< 0.001). Receiver operating characteristics (ROC) curve indicated that SUMO1P3 could be a potential tumor marker of NSCLC (AUC= 0.7284; 95% CI: 0.664-0.761; P= 0.0012). Kaplan-Meier survival analysis revealed that patients with high SUMO1P3 expression level had poorer overall survival (OS; P= 0.0001) and progression free survival (PFS; P= 0.0031) than those with low SUMO1P3 expression. Further multivariable Cox regression analysis suggested that increased SUMO1P3 was an independent prognostic indicator for this disease. In conclusion, SUMO1P3 is involved in the development and progression of NSCLC and may be a potential diagnostic and target for new therapies in patients with NSCLC.